VEGFA and glioblastoma: Glioblastoma are known for their high angiogenic capability and the secretion of high levels of VEGF[50], which might account for the variable effects of CM from breast, lung, prostate, and head and neck cancer models investigated in the current study compared to published glioblastoma data[32]; hence, the response of MSCs to tumor secreted factors can vary depending on the tumor type.